Macular Degeneration in Peru: Symptoms, Causes & Treatment | aihealz
OphthalmologymoderateICD-10 · H35.30
Macular Degeneration.Care & specialists in Peru
In Peru, macular Degeneration is managed by ophthalmologists. Age-related macular degeneration (AMD) is the leading cause of irreversible central vision loss in adults over 50 in high-income countries, driven by progressive damage to the macula — the small central region of the retina responsible for fine detail and reading vision. Roughly 200 million people worldwide live with some stage of AMD, and the global burden is projected to reach 288 million by 2040 as populations age.
Age-related macular degeneration (ICD-10: H35.3) is a chronic, progressive degenerative disease of the macula — a 5.5 mm zone at the centre of the retina that contains the highest density of cone photoreceptors and is responsible for sharp central vision, colour discrimination, and reading. The disease begins with the accumulation of yellow lipid-protein deposits called drusen between the retinal pigment epithelium (RPE) and Bruch's membrane, accompanied by oxidative stress, complement-pathway activation, and chronic low-grade inflammation. Two distinct late forms develop: in dry AMD (non-neovascular), areas of RPE and overlying photoreceptors die in expanding patches called geographic atrophy; in wet AMD (neovascular), abnormal choroidal blood vessels grow through Bruch's membrane into the subretinal space, leaking fluid and blood that scar the macula within weeks if untreated. AMD is staged by the AREDS classification as early, intermediate, or late based on drusen size, pigment changes, and presence of atrophy or neovascularization.
key facts
Prevalence
Roughly 200 million people worldwide; ~20 million US adults have some stage of AMD (NHANES 2005-2008 and 2019 update)
Demographics
Women slightly more affected than men; 2-3x higher prevalence in white populations than in Black or Hispanic populations at equivalent age
Avg. age
Early signs from age 50; late-stage disease typically presents from age 65 onward
Global cases
Projected to rise from 196 million (2020) to 288 million by 2040 (Wong 2014 Lancet Global Health)
Specialist
Ophthalmology
ICD-10
H35.30
§ 02
How you might notice it
The key symptoms of Macular Degeneration are: Gradual blurring of central vision in one or both eyes, most noticeable when reading small print, threading a needle, or recognizing a familiar face across a room., Straight lines appearing wavy, bent, or broken — a symptom called metamorphopsia, often first noticed when looking at door frames, window grids, or the Amsler grid given out by eye clinics., A dark, blurred, or empty patch in the centre of vision (central scotoma) that persists when the eye is moved, distinguishing it from a floater., Reduced ability to read in dim light and slower adaptation when moving from a bright room to a dim one, an early functional sign before standard visual acuity drops., Colours appearing less vivid or washed out, especially reds and yellows that depend on macular cones., Difficulty with high-contrast tasks such as recognizing road signs at dusk or distinguishing similar facial features., Sudden central vision loss or a new grey patch over several days — strongly suggests new wet AMD and requires same-week retinal review..
01Gradual blurring of central vision in one or both eyes, most noticeable when reading small print, threading a needle, or recognizing a familiar face across a room.
02Straight lines appearing wavy, bent, or broken — a symptom called metamorphopsia, often first noticed when looking at door frames, window grids, or the Amsler grid given out by eye clinics.
03A dark, blurred, or empty patch in the centre of vision (central scotoma) that persists when the eye is moved, distinguishing it from a floater.
04Reduced ability to read in dim light and slower adaptation when moving from a bright room to a dim one, an early functional sign before standard visual acuity drops.
§ 03
How it’s diagnosed
diagnosis
AMD is diagnosed clinically by a retinal specialist or comprehensive ophthalmologist using dilated fundus examination supported by multimodal retinal imaging. History elicits central blurring, metamorphopsia, scotoma, and difficulty with reading or face recognition; Amsler grid testing in the clinic and at home gives an immediate functional check. Dilated examination identifies drusen (size and number), pigmentary changes, geographic atrophy, subretinal fluid, haemorrhage, or fibrosis. The cornerstone imaging test is spectral-domain or swept-source optical coherence tomography (OCT), which resolves the retinal layers at 5-micron precision and detects subretinal or intraretinal fluid, drusenoid pigment epithelial detachments, and atrophic loss of the outer retinal bands. OCT angiography (OCTA) non-invasively visualizes choroidal neovascular networks without dye injection. Fundus autofluorescence maps geographic atrophy, and conventional fluorescein angiography is reserved for atypical cases where the diagnosis or activity of CNV is unclear. Indocyanine green angiography is added when polypoidal choroidal vasculopathy is suspected. Staging follows the AREDS scale (early, intermediate, late dry, late wet). The 2020 American Academy of Ophthalmology Preferred Practice Pattern for AMD recommends OCT and dilated examination at every visit, monthly home Amsler grid monitoring, and prompt referral to a retinal specialist within 1-2 weeks of any new metamorphopsia or scotoma in patients with intermediate AMD because of the time-critical window for anti-VEGF treatment in newly active neovascular disease.
Key tests
01
Dilated fundus examinationDirect visualization of the macula to identify drusen, pigment changes, geographic atrophy, haemorrhage, subretinal fluid, or fibrosis. The first-line screening and follow-up tool.
02
Spectral-domain or swept-source OCTCross-sectional imaging of the macula at micron-level resolution. Detects subretinal and intraretinal fluid, pigment epithelial detachments, outer-retinal atrophy, and drusen volume — the principal imaging modality for diagnosis and follow-up.
✓Ranibizumab (0.5 mg intravitreal injection, monthly or treat-and-extend)
✓Aflibercept (2 mg intravitreal injection every 8 weeks after loading; 8 mg high-dose extended-interval formulation approved 2023)
✓Brolucizumab (6 mg intravitreal injection every 8-12 weeks after loading)
surgical options
Intravitreal injection procedureEndophthalmitis risk per injection is roughly 1 in 3,000 in modern series; serious complications under 0.1% per injection.
Implantable Miniature Telescope (IMT)Roughly 60-75% of selected patients gain 3 lines of best-corrected acuity at 2 years (CentraSight registry); not suitable for most AMD patients.
Vitrectomy for submacular haemorrhageRoughly 40-60% achieve clinically meaningful visual improvement; outcomes depend on duration and extent of haemorrhage.
§ 05
Causes & risk factors
known causes
Accumulation of drusen and lipid-protein deposits
Photoreceptor outer segments are shed daily and digested by the retinal pigment epithelium. With age, undigested material accumulates as drusen between the RPE and Bruch's membrane, impairing nutrient and waste exchange and triggering local inflammation.
Oxidative stress in the macula
The macula has the highest oxygen consumption of any tissue per gram, and intense light exposure plus cumulative free-radical damage overwhelm antioxidant defences over decades. Oxidized lipids and proteins activate complement and damage RPE cells.
Complement-pathway dysregulation
Inherited variants in CFH, C3, CFB, and C2 raise lifetime AMD risk by 2-7 fold. The alternative complement cascade is chronically over-activated in the macula, producing membrane attack complex on RPE cells and driving geographic atrophy.
Choroidal neovascularization driven by VEGF
In wet AMD, hypoxic and inflamed RPE releases vascular endothelial growth factor (VEGF), which stimulates abnormal new vessel growth from the choroid through Bruch's membrane. These vessels are leaky and fragile, producing fluid, blood, and scar.
Mitochondrial dysfunction in RPE cells
Aged RPE mitochondria produce more reactive oxygen species and less ATP. Damaged cells trigger autophagy and apoptosis, depleting the support layer beneath the photoreceptors.
Chronic cigarette smoke exposure
Tobacco smoke depletes macular antioxidants, accelerates oxidative damage to Bruch's membrane, and constricts the choriocapillaris. Smokers reach the same AMD stage 5-10 years earlier than non-smokers.
risk factors
Age over 50
§ 06
Living with it
01Stop smoking — the single most powerful modifiable risk factor; risk falls progressively over the years after quitting
02Adopt a Mediterranean diet rich in green leafy vegetables, oily fish, nuts, olive oil, and minimal red meat — associated with up to 41% lower progression to late AMD
03Take AREDS2 supplements if you have intermediate AMD in either eye or late AMD in one eye, after discussing with your ophthalmologist
04Wear UV- and blue-light-protective sunglasses outdoors year-round to reduce cumulative phototoxic damage
05Control blood pressure, lipids, and weight — systemic vascular health correlates with choroidal blood flow and AMD progression
06Maintain regular cardiovascular exercise — observational data link physical activity to lower late AMD incidence
recommended foods
•Dark green leafy vegetables (kale, spinach, collards) — rich in lutein and zeaxanthin, the carotenoids that accumulate in macular pigment
•Oily fish 1-2 servings per week (salmon, sardines, mackerel, anchovies) — long-chain omega-3 fatty acids support retinal cell membranes
§ 07
When to seek help
why see an ophthalmology
A retinal specialist should be involved when there is intermediate or late AMD, any sign of metamorphopsia or new central scotoma, suspected wet AMD on OCT, or geographic atrophy being considered for complement inhibitor therapy. Comprehensive ophthalmologists and optometrists manage early AMD and provide ongoing monitoring between specialist visits. Same-week retinal review is essential for any new symptom suggesting wet AMD, because anti-VEGF treatment within 2 weeks of conversion preserves substantially more vision than delayed treatment.
01Severe central vision loss with legal blindness in the affected eye — usually preventable with timely anti-VEGF treatment in wet AMD, but irreversible once dense subretinal fibrosis develops
02Submacular haemorrhage from neovascular AMD — sudden dramatic vision drop; may require vitrectomy with tissue plasminogen activator and gas tamponade
03Progression to bilateral late AMD — risk in the fellow eye is roughly 40% within 5 years after first eye conversion to wet AMD without treatment
04Loss of independence, driving cessation, and increased fall risk — central scotomas affect depth perception and step navigation
05Endophthalmitis after intravitreal injection — rare (≈1 in 3,000 injections) but a sight-threatening emergency presenting with eye pain and vision drop within days
Early AMDMedium-sized drusen (63-125 microns) without pigment changes. Vision is normal. Roughly 18 million US adults are in this stage. Annual progression to late disease is under 1%.
Intermediate AMDLarge drusen (>125 microns) or pigmentary abnormalities in at least one eye. Vision is usually still 20/40 or better but contrast sensitivity falls. Five-year progression to late AMD is 15-25%, and AREDS2 supplementation reduces this risk by about 25%.
Dry (non-neovascular) AMD with geographic atrophyLate dry AMD with sharply demarcated patches of RPE and photoreceptor death. Vision loss is gradual over years. Accounts for the majority of late AMD by prevalence.
Wet (neovascular) AMDChoroidal neovascularization (CNV) breaks through Bruch's membrane, causing subretinal fluid, haemorrhage, or fibrosis. Without treatment, severe central vision loss occurs within 3 months in most patients.
Polypoidal choroidal vasculopathy (PCV)A neovascular AMD variant more common in East Asian and Black populations. Polyp-like vascular lesions of the inner choroid cause recurrent serosanguineous detachment. Requires distinct imaging (ICG angiography) and may need photodynamic therapy alongside anti-VEGF.
Living with Macular Degeneration
Timeline
For wet AMD treated with anti-VEGF, fluid on OCT typically resolves over 1-3 injections (4-12 weeks), with measurable visual acuity improvement in 4-8 weeks. Treatment is then maintained indefinitely at intervals of 4-16 weeks depending on individual response, often using a treat-and-extend protocol. Most patients require ongoing injections for many years; sudden cessation usually leads to fluid recurrence and vision loss within 3-6 months. For geographic atrophy, complement inhibitors slow progression over years but do not produce noticeable short-term visual change. Visual rehabilitation typically yields functional gains within 8-12 weeks of starting low-vision services.
Lifestyle
01Check an Amsler grid daily at home with reading glasses on, covering one eye at a time, and report any new wavy lines or missing squares the same day
02Schedule dilated retinal review every 6-12 months for intermediate AMD and every 4-8 weeks during active wet AMD treatment
03Optimize lighting at home — task lighting at the reading distance, matte non-glare surfaces, and high-contrast labels in the kitchen
04Adopt assistive technology early — large-print screens, screen readers, electronic magnifiers, and audiobooks preserve independence
05Continue to drive only after a low-vision driving evaluation; many patients with intermediate AMD continue to drive safely with restrictions
06Avoid intense direct sunlight at the beach, on snow, or during high-altitude activities without UV-blocking eyewear
07
Complementary approaches
Mediterranean diet patternHigher adherence to a Mediterranean dietary pattern was associated with a 41% lower risk of progression to advanced AMD in the EYE-RISK consortium and AREDS follow-up (Merle 2019 Ophthalmology). Not a substitute for AREDS2 supplementation but a meaningful adjunct.
Macular pigment supplementation with high-dose lutein and zeaxanthinBeyond AREDS2 doses, additional carotenoid supplementation increases macular pigment optical density and improves contrast sensitivity in some randomized trials, with uncertain effect on long-term progression.
Choosing a doctor
Look for board-certified retina or vitreoretinal subspecialists, fellowship-trained in medical retina, with high-volume experience in intravitreal injections (most retinal specialists perform 50-200 injections weekly). Ask whether the practice has OCT, OCT angiography, and access to fluorescein angiography on site, and whether they offer treat-and-extend protocols. For geographic atrophy, ask specifically about pegcetacoplan and avacincaptad pegol experience. Continuity matters — AMD is a multi-year condition where the same retinal specialist tracking your scans yields the best outcomes.
Macular degeneration is not curable, but it is highly treatable. Wet AMD responds to anti-VEGF injections that maintain or improve vision in about 90% of patients at 12 months. Dry AMD progression can be slowed with AREDS2 supplements and, for geographic atrophy, with complement inhibitors. Treatment is lifelong rather than a one-time fix.
What is the difference between wet and dry macular degeneration?▾▴
Dry AMD accounts for 85-90% of cases and progresses slowly through drusen accumulation and patchy retinal atrophy. Wet AMD accounts for 10-15% but causes most severe vision loss, driven by abnormal blood vessels growing under the macula that leak fluid and blood. Wet AMD is treated with anti-VEGF injections; dry AMD is managed with supplements and, for geographic atrophy, complement inhibitors.
Will I go completely blind from macular degeneration?▾▴
Total blindness from AMD is rare. The disease affects the central macula but spares peripheral retina, so even patients with advanced AMD usually retain enough peripheral vision to walk, orient themselves, and live independently. Legal blindness in the affected area is possible, but most patients keep useful side vision throughout life.
What are the first signs of macular degeneration?▾▴
Early signs include subtle blurring of central vision, difficulty reading small print in dim light, straight lines appearing slightly wavy on an Amsler grid, and colours looking less vivid. Drusen visible on a dilated retinal exam are often the first finding before any symptoms develop. Annual dilated eye exams after age 50 detect these changes.
How do anti-VEGF injections work?▾▴
Anti-VEGF drugs block vascular endothelial growth factor, the protein that drives abnormal blood vessel growth in wet AMD. They are injected into the vitreous cavity through the white of the eye under topical anaesthesia. The drug stops leakage and shrinks new vessels, allowing fluid to clear from the retina and vision to recover.
How often will I need eye injections?▾▴
Most patients start with monthly injections for three months (loading phase), then move to a treat-and-extend schedule that lengthens intervals to 8, 10, 12, or up to 16 weeks based on how the retina responds. Faricimab and high-dose aflibercept allow longer intervals than older agents. Injections continue indefinitely as long as the disease remains active.
Do AREDS2 vitamins prevent macular degeneration?▾▴
AREDS2 does not prevent AMD from starting and has no proven benefit in early AMD. In intermediate AMD or late AMD in one eye, AREDS2 reduces the 5-year risk of progression to late disease by approximately 25%. The formulation contains vitamins C and E, lutein, zeaxanthin, zinc, and copper.
Is macular degeneration hereditary?▾▴
Genetics account for roughly half of AMD risk. Variants in CFH, ARMS2/HTRA1, C3, and CFB raise lifetime risk 2-7 fold. Having a first-degree relative with AMD increases personal risk 3-4 fold. Lifestyle factors such as smoking, diet, and blood pressure interact strongly with genetic risk.
Does smoking cause macular degeneration?▾▴
Smoking is the strongest modifiable risk factor for AMD. Current smokers carry 2-4 times the risk of progression to late AMD compared with never-smokers. Cigarette smoke depletes macular antioxidants, damages Bruch's membrane, and restricts choroidal blood flow. Risk drops gradually after quitting, approaching never-smoker levels after about 20 years.
Can macular degeneration affect young people?▾▴
Age-related macular degeneration is rare before age 50. Younger patients with central vision loss usually have a different disease such as Stargardt disease, Best disease, juvenile retinoschisis, or central serous chorioretinopathy. A retinal specialist can distinguish these inherited and acquired macular conditions with genetic testing and imaging.
Will cataract surgery worsen macular degeneration?▾▴
Modern studies show that cataract surgery does not accelerate AMD progression. Removing a cloudy lens often improves residual visual function and allows better retinal monitoring. Most retinal specialists recommend stabilizing wet AMD with anti-VEGF injections before elective cataract surgery and timing surgery to avoid post-operative inflammation overlap.
What is geographic atrophy?▾▴
Geographic atrophy is an advanced form of dry AMD where patches of retinal pigment epithelium and overlying photoreceptors die in sharply demarcated zones. The patches expand at roughly 1.5-2.6 mm² per year. When atrophy reaches the foveal centre, reading vision is lost. Two complement inhibitors approved in 2023 slow this progression.
How effective are the new geographic atrophy treatments?▾▴
Pegcetacoplan and avacincaptad pegol are intravitreal complement inhibitors approved in 2023. They reduce the growth of geographic atrophy lesions by 14-22% over 12-24 months compared with sham injection. They do not restore lost vision and require monthly or bi-monthly injections, and patients should discuss benefits and risks with a retinal specialist.
How much does AMD treatment cost?▾▴
AREDS2 supplements cost roughly USD 15-25 per month. Anti-VEGF injections range from USD 50-100 per dose for off-label bevacizumab to USD 1,800-2,000 per dose for branded ranibizumab, aflibercept, brolucizumab, or faricimab in the US. Most US insurance plans and Medicare cover the procedure with substantial coinsurance. Costs in India and many emerging markets are lower, especially for bevacizumab.
Can I still drive with macular degeneration?▾▴
Many patients with early or intermediate AMD continue to drive safely. As central vision drops, driving becomes harder, particularly in low light or unfamiliar areas. A low-vision driving evaluation by a qualified optometrist or rehabilitation specialist determines whether someone meets local visual acuity and field requirements. Bioptic telescope systems extend driving for selected patients.
Do blue-light blocking glasses prevent AMD?▾▴
There is no high-quality randomized evidence that blue-light blocking glasses or computer screen filters prevent AMD. UV-blocking sunglasses outdoors are sensible because cumulative ultraviolet exposure is biologically plausible as a risk factor. The strongest preventive measures remain quitting smoking, eating a Mediterranean-style diet, and controlling blood pressure.
What is the Amsler grid and how do I use it?▾▴
The Amsler grid is a square chart with a central dot used to detect distortion or scotomas in central vision. Hold it at reading distance with your reading glasses on, cover one eye, look at the central dot, and check whether all lines appear straight and all squares present. Test each eye daily and report any new wavy lines or missing squares.
How is macular degeneration diagnosed?▾▴
Diagnosis begins with a dilated retinal exam to look for drusen, pigment changes, fluid, or haemorrhage. The key imaging test is optical coherence tomography (OCT), which images the retinal layers at micron resolution. OCT angiography, fundus autofluorescence, and occasionally fluorescein angiography characterize disease stage and activity. No blood test diagnoses AMD.
What are Charles Bonnet syndrome hallucinations?▾▴
Charles Bonnet syndrome is the experience of vivid visual hallucinations in patients with significant vision loss. The brain compensates for missing visual input by generating its own images, often patterns, faces, or animals. The hallucinations are harmless and the patient knows they are not real. Recognizing this syndrome reduces anxiety in 10-30% of late AMD patients who experience it.
Can macular degeneration be detected before symptoms appear?▾▴
Yes. Drusen and pigment changes that define early and intermediate AMD are visible on dilated retinal exam and OCT years before central vision changes. Annual or biennial dilated eye exams after age 50 are the standard recommendation, with more frequent monitoring for those with family history, smoking history, or known intermediate AMD.
Are intravitreal injections painful?▾▴
Most patients tolerate anti-VEGF injections well. The eye is anaesthetised with drops or a small subconjunctival injection, and the procedure itself takes seconds. Mild grittiness or redness for a day is normal. Severe pain after an injection is not normal and should prompt same-day eye review to exclude infection.
Does macular degeneration affect both eyes?▾▴
AMD often starts in one eye and spreads to the other over years. After wet AMD develops in one eye, the 5-year risk of wet AMD in the fellow eye is roughly 40% without preventive measures. Both eyes should be monitored, and an unaffected fellow eye gives independent confirmation of new symptoms when one eye is being treated.
05Colours appearing less vivid or washed out, especially reds and yellows that depend on macular cones.
06Difficulty with high-contrast tasks such as recognizing road signs at dusk or distinguishing similar facial features.
07Sudden central vision loss or a new grey patch over several days — strongly suggests new wet AMD and requires same-week retinal review.
08Distortion of the size or shape of objects (micropsia or macropsia) when viewed with one eye covered.
09Need for substantially brighter task lighting and larger print over months to years, often the first complaint that brings patients to an optometrist.
10Preserved peripheral vision throughout the disease — patients can usually walk and orient themselves, even with severe central scotomas, because the rod-dominated peripheral retina is spared.
early warning signs
•Subtle distortion of straight lines on an Amsler grid, often noticed first as a slight bend in a single horizontal line
•Drusen visible on routine dilated fundus examination or fundus photography in someone aged 50 or older
•A drop in low-contrast visual acuity (low-luminance reading) before standard high-contrast acuity changes
•Slow dark adaptation taking longer than 6 minutes — measurable on a dark-adaptometer and predictive of progression
•Family history of AMD in a parent or sibling, combined with current cigarette smoking
● emergency signs
•Sudden onset of new metamorphopsia, central scotoma, or a curtain of blur over central vision — schedule a same-week retina appointment to rule out new neovascular AMD or submacular haemorrhage
•Painless rapid vision loss accompanied by floaters and flashes — could represent retinal detachment in advanced AMD with macular hole, requiring urgent assessment
•Total loss of central vision over hours — rare in AMD itself, but can signal massive subretinal haemorrhage that benefits from urgent intervention
•New eye pain, redness, or vision drop within days of an intravitreal injection — possible endophthalmitis, which is an ophthalmic emergency
03
OCT angiography (OCTA)Visualizes choroidal and retinal blood flow without dye, identifying choroidal neovascular networks in wet AMD and capillary loss in geographic atrophy.
04
Fundus autofluorescence imagingMaps lipofuscin distribution in the RPE; geographic atrophy appears as sharply demarcated hypoautofluorescent areas. Used to track GA enlargement rate, a key endpoint in complement-inhibitor trials.
05
Fluorescein angiographyReserved for ambiguous cases where OCT and OCTA leave the diagnosis or activity unclear. Confirms leakage from choroidal neovascularization and characterizes lesion type (classic, occult, mixed).
06
Amsler grid (home and clinic)Functional self-monitoring tool for distortion or scotoma. Used daily by patients with intermediate AMD to detect early conversion to neovascular disease.
07
Indocyanine green angiographyIdentifies polypoidal choroidal vasculopathy and other choroidal vascular abnormalities not seen on fluorescein. Particularly important in patients of East Asian descent or with treatment-resistant wet AMD.
Outlook
Outcomes vary dramatically by stage and treatment. Early AMD has an excellent prognosis — most patients never progress to late disease in their lifetime, and routine monitoring is sufficient. Intermediate AMD carries a 5-year progression risk of 15-25% to late AMD, reduced to roughly 11-19% with AREDS2 supplementation. Wet AMD treated promptly with anti-VEGF preserves driving and reading vision in approximately 90% of patients at 12 months and 70-80% at 5 years in real-world registries; untreated, central vision typically drops below 20/200 within 3-6 months. Geographic atrophy progresses inexorably without treatment, expanding at roughly 1.5-2.6 mm² per year and reaching the foveal centre after a median of 2.5 years; complement inhibitors slow this rate by 14-22% but do not reverse vision loss. Peripheral vision is preserved at every stage of AMD, meaning legal blindness from this condition rarely means total loss of sight — patients can almost always orient themselves and walk independently. Adherence to treatment, regular monitoring, and low-vision rehabilitation are the strongest predictors of functional independence.
non-modifiable
Prevalence rises from about 2% at age 50-54 to over 30% by age 85. The single strongest risk factor.
European ancestrynon-modifiable
Late AMD is 2-3x more common in white populations than in Black or Hispanic populations, partly due to the CFH Y402H variant frequency and lower macular pigment in lighter-pigmented eyes.
Family history of AMDgenetic
Having a parent or sibling with AMD raises personal risk roughly 3-4 fold. Genome-wide studies have identified more than 50 risk loci, with CFH and ARMS2/HTRA1 carrying the largest effect sizes.
Current cigarette smokingmodifiable
Smokers carry 2-4x the risk of progression to late AMD compared with never-smokers; risk falls toward never-smoker levels roughly 20 years after quitting.
Hypertension and cardiovascular diseasemodifiable
Choroidal blood flow declines with systemic vascular disease; treated hypertension reduces wet AMD incidence in some cohort studies.
Obesity (BMI ≥30)modifiable
Higher BMI is associated with 2x risk of progression from intermediate to late AMD in AREDS data, possibly via systemic inflammation.
Diet low in carotenoids and oily fishmodifiable
Low dietary lutein, zeaxanthin, and omega-3 fatty acids correlate with higher AMD incidence; the Mediterranean diet reduces progression to late AMD by about 25% (Merle 2019 Ophthalmology).
Light iris colour and high sun exposureenvironmental
Blue and green irises let more short-wavelength light reach the retina, and cumulative UV/blue-light exposure correlates with drusen burden in some studies.
Female sexnon-modifiable
Late AMD prevalence is roughly 1.4x higher in women than men, partly reflecting greater longevity.
AMD in the fellow eyenon-modifiable
If one eye has late AMD, the 5-year risk in the other eye is roughly 40% in untreated wet AMD and 25% in geographic atrophy. This drives aggressive monitoring and early treatment.
•Nuts and olive oil — monounsaturated fats characteristic of the Mediterranean pattern
•Whole grains and legumes — slow-release carbohydrates with lower glycemic index, which is associated with lower AMD progression
•Adequate water and unsweetened beverages
foods to avoid
•Beta-carotene supplements if you are a current or former smoker — raised lung cancer risk in AREDS
•High-glycemic-index processed carbohydrates (white bread, sweetened breakfast cereals) — observational data link high dietary glycemic index to faster AMD progression
•Heavy red and processed meat consumption — pro-inflammatory dietary pattern associated with higher progression rates
•Trans fats and frequent deep-fried foods
•Tobacco in any form, including secondhand smoke exposure
•Excessive alcohol — more than 3 drinks daily correlates with higher early AMD incidence in some cohorts
06Charles Bonnet syndrome — vivid visual hallucinations in patients with severe vision loss, harmless but distressing if not recognized; affects an estimated 10-30% of AMD patients with late disease
Stay current with vaccinations, dental care, and diabetes/blood pressure follow-up — systemic infections during anti-VEGF treatment are a relative concern for injection timing
Daily management
01Perform the Amsler grid test each morning with reading correction, one eye at a time, and call the eye clinic the same day for any new distortion
02Take AREDS2 once daily with food if prescribed; consistency is more important than time of day
03Use prescribed reading glasses, magnifiers, or electronic visual aids at the lighting level your low-vision optometrist recommends
04Keep a record of injection dates, scan dates, and visual acuity readings — useful when transitioning between practices or specialists
05Wear UV-protective sunglasses outdoors and avoid sun glare during peak hours
Exercise
Aerobic exercise such as walking, cycling, or swimming for at least 150 minutes weekly is associated with lower AMD incidence and progression in observational studies. Resistance training twice weekly supports overall cardiovascular and metabolic health. There are no exercise restrictions specific to AMD, but patients on anti-VEGF injections should avoid eye trauma in the first 24-48 hours after injection.